Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 15-minute fosnetupitant infusion in solid tumors
jRCT1041220144Completed
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fosnetupitant in Nonhematologic neoplasms, breast cancer, gastrointestinal cancer and 1 more. Primary endpoint: Incidence of allergic reaction at first 15-minute fosnetupitant infusion. Started Feb 2023; status: completed.
02
Drugs
fosnetupitant
03
Conditions
Nonhematologic neoplasmsbreast cancergastrointestinal cancerchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT1041220144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041220144.